COVID-19 Impact on Global Biosimilar Insulin, Market Insights and Forecast to 2026
- BMR3903670
- 113 Pages
- June 2020
- Healthcare
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Biosimilar Insulin industry.
Based on our recent survey, we have several different scenarios about the Biosimilar Insulin YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Biosimilar Insulin will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Biosimilar Insulin market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Biosimilar Insulin market in terms of both revenue and volume.
Players, stakeholders, and other participants in the global Biosimilar Insulin market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Sales and Pricing Analyses
Readers are provided with deeper sales analysis and pricing analysis for the global Biosimilar Insulin market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.
In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Biosimilar Insulin market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Biosimilar Insulin market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Biosimilar Insulin market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Biosimilar Insulin market.
The following manufacturers are covered in this report:
Pfizer
Biogenomics
Eli Lilly
Gan&Lee Pharmaceuticals
Geropharm
Julphar Gulf Pharmaceutical Industries
Paras Biopharmaceuticals
Samsung Bioepis
Sedico
Wockhardt
Teva Pharmaceuticals
Biosimilar Insulin Breakdown Data by Type
Rapid Acting Insulins
Short Acting Insulins
Intermediate Insulins
Long Lasting Insulins
Biosimilar Insulin Breakdown Data by Application
Hospital
Clinic
Medical Center
1.1 Biosimilar Insulin Product Introduction
1.2 Market Segments
1.3 Key Biosimilar Insulin Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Biosimilar Insulin Market Size Growth Rate by Type
1.4.2 Rapid Acting Insulins
1.4.3 Short Acting Insulins
1.4.4 Intermediate Insulins
1.4.5 Long Lasting Insulins
1.5 Market by Application
1.5.1 Global Biosimilar Insulin Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Medical Center
1.6 Coronavirus Disease 2019 (Covid-19): Biosimilar Insulin Industry Impact
1.6.1 How the Covid-19 is Affecting the Biosimilar Insulin Industry
1.6.1.1 Biosimilar Insulin Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Biosimilar Insulin Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Biosimilar Insulin Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Biosimilar Insulin Market Size Estimates and Forecasts
2.1.1 Global Biosimilar Insulin Revenue 2015-2026
2.1.2 Global Biosimilar Insulin Sales 2015-2026
2.2 Biosimilar Insulin Market Size by Region: 2020 Versus 2026
2.2.1 Global Biosimilar Insulin Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Biosimilar Insulin Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Biosimilar Insulin Competitor Landscape by Players
3.1 Biosimilar Insulin Sales by Manufacturers
3.1.1 Biosimilar Insulin Sales by Manufacturers (2015-2020)
3.1.2 Biosimilar Insulin Sales Market Share by Manufacturers (2015-2020)
3.2 Biosimilar Insulin Revenue by Manufacturers
3.2.1 Biosimilar Insulin Revenue by Manufacturers (2015-2020)
3.2.2 Biosimilar Insulin Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Biosimilar Insulin Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Biosimilar Insulin Revenue in 2019
3.2.5 Global Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Biosimilar Insulin Price by Manufacturers
3.4 Biosimilar Insulin Manufacturing Base Distribution, Product Types
3.4.1 Biosimilar Insulin Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Biosimilar Insulin Product Type
3.4.3 Date of International Manufacturers Enter into Biosimilar Insulin Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Biosimilar Insulin Market Size by Type (2015-2020)
4.1.1 Global Biosimilar Insulin Sales by Type (2015-2020)
4.1.2 Global Biosimilar Insulin Revenue by Type (2015-2020)
4.1.3 Biosimilar Insulin Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Biosimilar Insulin Market Size Forecast by Type (2021-2026)
4.2.1 Global Biosimilar Insulin Sales Forecast by Type (2021-2026)
4.2.2 Global Biosimilar Insulin Revenue Forecast by Type (2021-2026)
4.2.3 Biosimilar Insulin Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Biosimilar Insulin Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)
5.1 Global Biosimilar Insulin Market Size by Application (2015-2020)
5.1.1 Global Biosimilar Insulin Sales by Application (2015-2020)
5.1.2 Global Biosimilar Insulin Revenue by Application (2015-2020)
5.1.3 Biosimilar Insulin Price by Application (2015-2020)
5.2 Biosimilar Insulin Market Size Forecast by Application (2021-2026)
5.2.1 Global Biosimilar Insulin Sales Forecast by Application (2021-2026)
5.2.2 Global Biosimilar Insulin Revenue Forecast by Application (2021-2026)
5.2.3 Global Biosimilar Insulin Price Forecast by Application (2021-2026)
6 North America
6.1 North America Biosimilar Insulin by Country
6.1.1 North America Biosimilar Insulin Sales by Country
6.1.2 North America Biosimilar Insulin Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Biosimilar Insulin Market Facts & Figures by Type
6.3 North America Biosimilar Insulin Market Facts & Figures by Application
7 Europe
7.1 Europe Biosimilar Insulin by Country
7.1.1 Europe Biosimilar Insulin Sales by Country
7.1.2 Europe Biosimilar Insulin Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Biosimilar Insulin Market Facts & Figures by Type
7.3 Europe Biosimilar Insulin Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Biosimilar Insulin by Region
8.1.1 Asia Pacific Biosimilar Insulin Sales by Region
8.1.2 Asia Pacific Biosimilar Insulin Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Biosimilar Insulin Market Facts & Figures by Type
8.3 Asia Pacific Biosimilar Insulin Market Facts & Figures by Application
9 Latin America
9.1 Latin America Biosimilar Insulin by Country
9.1.1 Latin America Biosimilar Insulin Sales by Country
9.1.2 Latin America Biosimilar Insulin Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Biosimilar Insulin Market Facts & Figures by Type
9.3 Central & South America Biosimilar Insulin Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Biosimilar Insulin by Country
10.1.1 Middle East and Africa Biosimilar Insulin Sales by Country
10.1.2 Middle East and Africa Biosimilar Insulin Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Type
10.3 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Application
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description, Business Overview and Total Revenue
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Biosimilar Insulin Products Offered
11.1.5 Pfizer Recent Development
11.2 Biogenomics
11.2.1 Biogenomics Corporation Information
11.2.2 Biogenomics Description, Business Overview and Total Revenue
11.2.3 Biogenomics Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Biogenomics Biosimilar Insulin Products Offered
11.2.5 Biogenomics Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Description, Business Overview and Total Revenue
11.3.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Eli Lilly Biosimilar Insulin Products Offered
11.3.5 Eli Lilly Recent Development
11.4 Gan&Lee Pharmaceuticals
11.4.1 Gan&Lee Pharmaceuticals Corporation Information
11.4.2 Gan&Lee Pharmaceuticals Description, Business Overview and Total Revenue
11.4.3 Gan&Lee Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Gan&Lee Pharmaceuticals Biosimilar Insulin Products Offered
11.4.5 Gan&Lee Pharmaceuticals Recent Development
11.5 Geropharm
11.5.1 Geropharm Corporation Information
11.5.2 Geropharm Description, Business Overview and Total Revenue
11.5.3 Geropharm Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Geropharm Biosimilar Insulin Products Offered
11.5.5 Geropharm Recent Development
11.6 Julphar Gulf Pharmaceutical Industries
11.6.1 Julphar Gulf Pharmaceutical Industries Corporation Information
11.6.2 Julphar Gulf Pharmaceutical Industries Description, Business Overview and Total Revenue
11.6.3 Julphar Gulf Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Products Offered
11.6.5 Julphar Gulf Pharmaceutical Industries Recent Development
11.7 Paras Biopharmaceuticals
11.7.1 Paras Biopharmaceuticals Corporation Information
11.7.2 Paras Biopharmaceuticals Description, Business Overview and Total Revenue
11.7.3 Paras Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Paras Biopharmaceuticals Biosimilar Insulin Products Offered
11.7.5 Paras Biopharmaceuticals Recent Development
11.8 Samsung Bioepis
11.8.1 Samsung Bioepis Corporation Information
11.8.2 Samsung Bioepis Description, Business Overview and Total Revenue
11.8.3 Samsung Bioepis Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Samsung Bioepis Biosimilar Insulin Products Offered
11.8.5 Samsung Bioepis Recent Development
11.9 Sedico
11.9.1 Sedico Corporation Information
11.9.2 Sedico Description, Business Overview and Total Revenue
11.9.3 Sedico Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sedico Biosimilar Insulin Products Offered
11.9.5 Sedico Recent Development
11.10 Wockhardt
11.10.1 Wockhardt Corporation Information
11.10.2 Wockhardt Description, Business Overview and Total Revenue
11.10.3 Wockhardt Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Wockhardt Biosimilar Insulin Products Offered
11.10.5 Wockhardt Recent Development
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description, Business Overview and Total Revenue
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Biosimilar Insulin Products Offered
11.1.5 Pfizer Recent Development
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Biosimilar Insulin Market Estimates and Projections by Region
12.1.1 Global Biosimilar Insulin Sales Forecast by Regions 2021-2026
12.1.2 Global Biosimilar Insulin Revenue Forecast by Regions 2021-2026
12.2 North America Biosimilar Insulin Market Size Forecast (2021-2026)
12.2.1 North America: Biosimilar Insulin Sales Forecast (2021-2026)
12.2.2 North America: Biosimilar Insulin Revenue Forecast (2021-2026)
12.2.3 North America: Biosimilar Insulin Market Size Forecast by Country (2021-2026)
12.3 Europe Biosimilar Insulin Market Size Forecast (2021-2026)
12.3.1 Europe: Biosimilar Insulin Sales Forecast (2021-2026)
12.3.2 Europe: Biosimilar Insulin Revenue Forecast (2021-2026)
12.3.3 Europe: Biosimilar Insulin Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Biosimilar Insulin Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Biosimilar Insulin Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Biosimilar Insulin Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Biosimilar Insulin Market Size Forecast by Region (2021-2026)
12.5 Latin America Biosimilar Insulin Market Size Forecast (2021-2026)
12.5.1 Latin America: Biosimilar Insulin Sales Forecast (2021-2026)
12.5.2 Latin America: Biosimilar Insulin Revenue Forecast (2021-2026)
12.5.3 Latin America: Biosimilar Insulin Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Biosimilar Insulin Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Biosimilar Insulin Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Biosimilar Insulin Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Biosimilar Insulin Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Biosimilar Insulin Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Biosimilar Insulin Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
Table 1. Biosimilar Insulin Market Segments
Table 2. Ranking of Global Top Biosimilar Insulin Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Biosimilar Insulin Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Rapid Acting Insulins
Table 5. Major Manufacturers of Short Acting Insulins
Table 6. Major Manufacturers of Intermediate Insulins
Table 7. Major Manufacturers of Long Lasting Insulins
Table 8. COVID-19 Impact Global Market: (Four Biosimilar Insulin Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Biosimilar Insulin Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Biosimilar Insulin Players to Combat Covid-19 Impact
Table 13. Global Biosimilar Insulin Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 14. Global Biosimilar Insulin Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 15. Global Biosimilar Insulin Sales by Regions 2015-2020 (K Pcs)
Table 16. Global Biosimilar Insulin Sales Market Share by Regions (2015-2020)
Table 17. Global Biosimilar Insulin Revenue by Regions 2015-2020 (US$ Million)
Table 18. Global Biosimilar Insulin Sales by Manufacturers (2015-2020) (K Pcs)
Table 19. Global Biosimilar Insulin Sales Share by Manufacturers (2015-2020)
Table 20. Global Biosimilar Insulin Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 21. Global Biosimilar Insulin by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biosimilar Insulin as of 2019)
Table 22. Biosimilar Insulin Revenue by Manufacturers (2015-2020) (US$ Million)
Table 23. Biosimilar Insulin Revenue Share by Manufacturers (2015-2020)
Table 24. Key Manufacturers Biosimilar Insulin Price (2015-2020) (USD/Pcs)
Table 25. Biosimilar Insulin Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Biosimilar Insulin Product Type
Table 27. Date of International Manufacturers Enter into Biosimilar Insulin Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Biosimilar Insulin Sales by Type (2015-2020) (K Pcs)
Table 30. Global Biosimilar Insulin Sales Share by Type (2015-2020)
Table 31. Global Biosimilar Insulin Revenue by Type (2015-2020) (US$ Million)
Table 32. Global Biosimilar Insulin Revenue Share by Type (2015-2020)
Table 33. Biosimilar Insulin Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 34. Global Biosimilar Insulin Sales by Application (2015-2020) (K Pcs)
Table 35. Global Biosimilar Insulin Sales Share by Application (2015-2020)
Table 36. North America Biosimilar Insulin Sales by Country (2015-2020) (K Pcs)
Table 37. North America Biosimilar Insulin Sales Market Share by Country (2015-2020)
Table 38. North America Biosimilar Insulin Revenue by Country (2015-2020) (US$ Million)
Table 39. North America Biosimilar Insulin Revenue Market Share by Country (2015-2020)
Table 40. North America Biosimilar Insulin Sales by Type (2015-2020) (K Pcs)
Table 41. North America Biosimilar Insulin Sales Market Share by Type (2015-2020)
Table 42. North America Biosimilar Insulin Sales by Application (2015-2020) (K Pcs)
Table 43. North America Biosimilar Insulin Sales Market Share by Application (2015-2020)
Table 44. Europe Biosimilar Insulin Sales by Country (2015-2020) (K Pcs)
Table 45. Europe Biosimilar Insulin Sales Market Share by Country (2015-2020)
Table 46. Europe Biosimilar Insulin Revenue by Country (2015-2020) (US$ Million)
Table 47. Europe Biosimilar Insulin Revenue Market Share by Country (2015-2020)
Table 48. Europe Biosimilar Insulin Sales by Type (2015-2020) (K Pcs)
Table 49. Europe Biosimilar Insulin Sales Market Share by Type (2015-2020)
Table 50. Europe Biosimilar Insulin Sales by Application (2015-2020) (K Pcs)
Table 51. Europe Biosimilar Insulin Sales Market Share by Application (2015-2020)
Table 52. Asia Pacific Biosimilar Insulin Sales by Region (2015-2020) (K Pcs)
Table 53. Asia Pacific Biosimilar Insulin Sales Market Share by Region (2015-2020)
Table 54. Asia Pacific Biosimilar Insulin Revenue by Region (2015-2020) (US$ Million)
Table 55. Asia Pacific Biosimilar Insulin Revenue Market Share by Region (2015-2020)
Table 56. Asia Pacific Biosimilar Insulin Sales by Type (2015-2020) (K Pcs)
Table 57. Asia Pacific Biosimilar Insulin Sales Market Share by Type (2015-2020)
Table 58. Asia Pacific Biosimilar Insulin Sales by Application (2015-2020) (K Pcs)
Table 59. Asia Pacific Biosimilar Insulin Sales Market Share by Application (2015-2020)
Table 60. Latin America Biosimilar Insulin Sales by Country (2015-2020) (K Pcs)
Table 61. Latin America Biosimilar Insulin Sales Market Share by Country (2015-2020)
Table 62. Latin Americaa Biosimilar Insulin Revenue by Country (2015-2020) (US$ Million)
Table 63. Latin America Biosimilar Insulin Revenue Market Share by Country (2015-2020)
Table 64. Latin America Biosimilar Insulin Sales by Type (2015-2020) (K Pcs)
Table 65. Latin America Biosimilar Insulin Sales Market Share by Type (2015-2020)
Table 66. Latin America Biosimilar Insulin Sales by Application (2015-2020) (K Pcs)
Table 67. Latin America Biosimilar Insulin Sales Market Share by Application (2015-2020)
Table 68. Middle East and Africa Biosimilar Insulin Sales by Country (2015-2020) (K Pcs)
Table 69. Middle East and Africa Biosimilar Insulin Sales Market Share by Country (2015-2020)
Table 70. Middle East and Africa Biosimilar Insulin Revenue by Country (2015-2020) (US$ Million)
Table 71. Middle East and Africa Biosimilar Insulin Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Biosimilar Insulin Sales by Type (2015-2020) (K Pcs)
Table 73. Middle East and Africa Biosimilar Insulin Sales Market Share by Type (2015-2020)
Table 74. Middle East and Africa Biosimilar Insulin Sales by Application (2015-2020) (K Pcs)
Table 75. Middle East and Africa Biosimilar Insulin Sales Market Share by Application (2015-2020)
Table 76. Pfizer Corporation Information
Table 77. Pfizer Description and Major Businesses
Table 78. Pfizer Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. Pfizer Product
Table 80. Pfizer Recent Development
Table 81. Biogenomics Corporation Information
Table 82. Biogenomics Description and Major Businesses
Table 83. Biogenomics Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Biogenomics Product
Table 85. Biogenomics Recent Development
Table 86. Eli Lilly Corporation Information
Table 87. Eli Lilly Description and Major Businesses
Table 88. Eli Lilly Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Eli Lilly Product
Table 90. Eli Lilly Recent Development
Table 91. Gan&Lee Pharmaceuticals Corporation Information
Table 92. Gan&Lee Pharmaceuticals Description and Major Businesses
Table 93. Gan&Lee Pharmaceuticals Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. Gan&Lee Pharmaceuticals Product
Table 95. Gan&Lee Pharmaceuticals Recent Development
Table 96. Geropharm Corporation Information
Table 97. Geropharm Description and Major Businesses
Table 98. Geropharm Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Geropharm Product
Table 100. Geropharm Recent Development
Table 101. Julphar Gulf Pharmaceutical Industries Corporation Information
Table 102. Julphar Gulf Pharmaceutical Industries Description and Major Businesses
Table 103. Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. Julphar Gulf Pharmaceutical Industries Product
Table 105. Julphar Gulf Pharmaceutical Industries Recent Development
Table 106. Paras Biopharmaceuticals Corporation Information
Table 107. Paras Biopharmaceuticals Description and Major Businesses
Table 108. Paras Biopharmaceuticals Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. Paras Biopharmaceuticals Product
Table 110. Paras Biopharmaceuticals Recent Development
Table 111. Samsung Bioepis Corporation Information
Table 112. Samsung Bioepis Description and Major Businesses
Table 113. Samsung Bioepis Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 114. Samsung Bioepis Product
Table 115. Samsung Bioepis Recent Development
Table 116. Sedico Corporation Information
Table 117. Sedico Description and Major Businesses
Table 118. Sedico Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 119. Sedico Product
Table 120. Sedico Recent Development
Table 121. Wockhardt Corporation Information
Table 122. Wockhardt Description and Major Businesses
Table 123. Wockhardt Biosimilar Insulin Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 124. Wockhardt Product
Table 125. Wockhardt Recent Development
Table 126. Teva Pharmaceuticals Corporation Information
Table 127. Teva Pharmaceuticals Description and Major Businesses
Table 128. Teva Pharmaceuticals Biosimilar Insulin Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 129. Teva Pharmaceuticals Product
Table 130. Teva Pharmaceuticals Recent Development
Table 131. Global Biosimilar Insulin Sales Forecast by Regions (2021-2026) (K Pcs)
Table 132. Global Biosimilar Insulin Sales Market Share Forecast by Regions (2021-2026)
Table 133. Global Biosimilar Insulin Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 134. Global Biosimilar Insulin Revenue Market Share Forecast by Regions (2021-2026)
Table 135. North America: Biosimilar Insulin Sales Forecast by Country (2021-2026) (K Pcs)
Table 136. North America: Biosimilar Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Europe: Biosimilar Insulin Sales Forecast by Country (2021-2026) (K Pcs)
Table 138. Europe: Biosimilar Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Asia Pacific: Biosimilar Insulin Sales Forecast by Region (2021-2026) (K Pcs)
Table 140. Asia Pacific: Biosimilar Insulin Revenue Forecast by Region (2021-2026) (US$ Million)
Table 141. Latin America: Biosimilar Insulin Sales Forecast by Country (2021-2026) (K Pcs)
Table 142. Latin America: Biosimilar Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Middle East and Africa: Biosimilar Insulin Sales Forecast by Country (2021-2026) (K Pcs)
Table 144. Middle East and Africa: Biosimilar Insulin Revenue Forecast by Country (2021-2026) (US$ Million)
Table 145. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 146. Key Challenges
Table 147. Market Risks
Table 148. Main Points Interviewed from Key Biosimilar Insulin Players
Table 149. Biosimilar Insulin Customers List
Table 150. Biosimilar Insulin Distributors List
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Insulin Product Picture
Figure 2. Global Biosimilar Insulin Sales Market Share by Type in 2020 & 2026
Figure 3. Rapid Acting Insulins Product Picture
Figure 4. Short Acting Insulins Product Picture
Figure 5. Intermediate Insulins Product Picture
Figure 6. Long Lasting Insulins Product Picture
Figure 7. Global Biosimilar Insulin Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Medical Center
Figure 11. Biosimilar Insulin Report Years Considered
Figure 12. Global Biosimilar Insulin Market Size 2015-2026 (US$ Million)
Figure 13. Global Biosimilar Insulin Sales 2015-2026 (K Pcs)
Figure 14. Global Biosimilar Insulin Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Biosimilar Insulin Sales Market Share by Region (2015-2020)
Figure 16. Global Biosimilar Insulin Sales Market Share by Region in 2019
Figure 17. Global Biosimilar Insulin Revenue Market Share by Region (2015-2020)
Figure 18. Global Biosimilar Insulin Revenue Market Share by Region in 2019
Figure 19. Global Biosimilar Insulin Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Biosimilar Insulin Revenue in 2019
Figure 21. Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Biosimilar Insulin Sales Market Share by Type (2015-2020)
Figure 23. Global Biosimilar Insulin Sales Market Share by Type in 2019
Figure 24. Global Biosimilar Insulin Revenue Market Share by Type (2015-2020)
Figure 25. Global Biosimilar Insulin Revenue Market Share by Type in 2019
Figure 26. Global Biosimilar Insulin Market Share by Price Range (2015-2020)
Figure 27. Global Biosimilar Insulin Sales Market Share by Application (2015-2020)
Figure 28. Global Biosimilar Insulin Sales Market Share by Application in 2019
Figure 29. Global Biosimilar Insulin Revenue Market Share by Application (2015-2020)
Figure 30. Global Biosimilar Insulin Revenue Market Share by Application in 2019
Figure 31. North America Biosimilar Insulin Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Biosimilar Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Biosimilar Insulin Sales Market Share by Country in 2019
Figure 34. North America Biosimilar Insulin Revenue Market Share by Country in 2019
Figure 35. U.S. Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Biosimilar Insulin Market Share by Type in 2019
Figure 40. North America Biosimilar Insulin Market Share by Application in 2019
Figure 41. Europe Biosimilar Insulin Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Biosimilar Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Biosimilar Insulin Sales Market Share by Country in 2019
Figure 44. Europe Biosimilar Insulin Revenue Market Share by Country in 2019
Figure 45. Germany Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Biosimilar Insulin Market Share by Type in 2019
Figure 56. Europe Biosimilar Insulin Market Share by Application in 2019
Figure 57. Asia Pacific Biosimilar Insulin Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Biosimilar Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Biosimilar Insulin Sales Market Share by Region in 2019
Figure 60. Asia Pacific Biosimilar Insulin Revenue Market Share by Region in 2019
Figure 61. China Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Biosimilar Insulin Market Share by Type in 2019
Figure 84. Asia Pacific Biosimilar Insulin Market Share by Application in 2019
Figure 85. Latin America Biosimilar Insulin Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Biosimilar Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Biosimilar Insulin Sales Market Share by Country in 2019
Figure 88. Latin America Biosimilar Insulin Revenue Market Share by Country in 2019
Figure 89. Mexico Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Biosimilar Insulin Market Share by Type in 2019
Figure 96. Latin America Biosimilar Insulin Market Share by Application in 2019
Figure 97. Middle East and Africa Biosimilar Insulin Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Biosimilar Insulin Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Biosimilar Insulin Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Biosimilar Insulin Revenue Market Share by Country in 2019
Figure 101. Turkey Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Biosimilar Insulin Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Biosimilar Insulin Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Biosimilar Insulin Market Share by Type in 2019
Figure 108. Middle East and Africa Biosimilar Insulin Market Share by Application in 2019
Figure 109. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Biogenomics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Gan&Lee Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Geropharm Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Julphar Gulf Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Paras Biopharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Samsung Bioepis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Sedico Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Wockhardt Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Teva Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. North America Biosimilar Insulin Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 121. North America Biosimilar Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Europe Biosimilar Insulin Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 123. Europe Biosimilar Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Asia Pacific Biosimilar Insulin Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 125. Asia Pacific Biosimilar Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Latin America Biosimilar Insulin Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 127. Latin America Biosimilar Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Middle East and Africa Biosimilar Insulin Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 129. Middle East and Africa Biosimilar Insulin Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 130. Porter's Five Forces Analysis
Figure 131. Channels of Distribution
Figure 132. Distributors Profiles
Figure 133. Bottom-up and Top-down Approaches for This Report
Figure 134. Data Triangulation
Figure 135. Key Executives Interviewed
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
